02:40:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
IndustriLäkemedel & Handel
Lipum är ett biofarmaceutiskt bolag specialiserat på utveckling av ny behandling för kroniska inflammatoriska sjukdomar. Läkemedelskandidaten SOL-116 är en humaniserad antikropp som blockerar en tidigare förbisedd målmolekyl (BSSL) i immunförsvaret. Bolaget är i första hand inriktade på den sällsynta sjukdomen barnreumatism samt ledgångsreumatism, men utvärderar även en rad andra inflammatoriska sjukdomar. Lipum har sin verksamhet i Umeå.


2023-03-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-10-12 Extra Bolagsstämma 2022
2022-07-27 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Ordinarie utdelning LIPUM 0.00 SEK
2022-04-26 Årsstämma 2022
2022-03-25 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-26 Kvartalsrapport 2021-Q3
2022-05-18 08:30:00
Press release: Umeå, 18 May 2022. Lipum AB (publ) has published the interim report for period January to March for 2022. Below is a summary, a complete report (only in Swedish) is available on the company's website (https://lipum.se/finansiella-rapporter/).

CEO Einar Pontén comments: “More progress was made in the preparations ahead of clinical trials. In parallel, and in accordance with our strategy, we strengthened our pre-clinical activities.”

Financial summary January - March 2022

  • Net sales: KSEK 0 (0)
  • Result after financial items: KSEK -5,830 (-6,109)
  • Cash and cash equivalents as of March 31: KSEK 27,971 (4,165)

Significant events during the period January - March 2022

  • The GMP production of SOL-116 for clinical trials was finalized
  • Startup agreement for the phase I clinical trial was signed with QPS Netherlands BV
  • The company's organization for preclinical development was strengthened

Significant events after the period

  • Scientific abstract accepted by EULAR 2022, a European Congress of Rheumatology
  • Continued collaboration with Cardiovascular Research Center (CVRC) at Örebro University in Sweden which was granted further research funding from the Knowledge Foundation

Link to the full report (in Swedish): Interim report

CEO Einar Pontén comments on the report in a live webcast on May 18 at 14:00, link.

For further information, please contact: 
Einar Pontén, CEO
E-post:    einar.ponten@lipum.se
Mobil:     +46 70 578 34 95
Web:       www.lipum.se

About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se, phone: +46 8 503 000 50.